Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence

Drug and Alcohol Dependence

Volumn 109, Issue 1-3, 2010, Pages 20-29

  Heinzerling, Keith G ^a,b   Swanson, Aimee Noelle ^a   Kim, Soeun ^a   Cederblom, Lisa ^a   Moe, Ardis ^a   Ling, Walter ^a,b   Shoptaw, Steven ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Methamphetamine; Modafinil; Pharmacotherapy; Randomized clinical trial

Indexed keywords

METHAMPHETAMINE; MODAFINIL; PLACEBO;

ADULT; ANXIETY; ARTICLE; BLOOD PRESSURE; CIGARETTE SMOKING; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EDUCATIONAL STATUS; EMPLOYMENT STATUS; FEMALE; HEADACHE; HEART RATE; HUMAN; INCOME; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MORNING DOSAGE; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINALYSIS; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; AMPHETAMINE-RELATED DISORDERS; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITIVE THERAPY; COUNSELING; DATA INTERPRETATION, STATISTICAL; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHAMPHETAMINE; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; SMOKING; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE DETECTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953024401     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2009.11.023     Document Type: Article

References (56)

1. Anderson A.L., Reid M.S., Li S.H., Holmes T., Shemanski L., Slee A., Smith E.V., Kahn R., Chiang N., Vocci F., Ciraulo D., Dackis C., Roache J.D., Salloum I.M., Somoza E., Urschel H.C., Elkashef A.M. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend. 2009, 104:133-139.
2. Anton R.F., O'Malley S.S., Ciraulo D.A., Cisler R.A., Couper D., Donovan D.M., Gastfriend D.R., Hosking J.D., Johnson B.A., LoCastro J.S., Longabaugh R., Mason B.J., Mattson M.E., Miller W.R., Pettinati H.M., Randall C.L., Swift R., Weiss R.D., Williams L.D., Zweben A. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006, 295:2003-2017.
3. Batki S., Moon J., Delucchi K., Hersh D., Bradley M., Aguillon-Doms C., Mendelson J., Jones R., Panganiban T., Everhart T., Mengis M., Smolar S., Helmke H., Jacob P. Amlodipine treatment of methamphetamine dependence, a controlled outpatient trial: preliminary analysis. The 63rd Annual Scientific Meeting of the College on Problems of Drug Dependence 2001.
4. Batki S.L., Moon J., Bradley M., Hersh D., Smolar S., Mengis M., Delucchi K., Sexe D., Bennett S., Lefkowitz E., Chu W., Morello L., Jacob P., Jones R.T. Fluoxetine in methamphetamine dependence-a controlled trial: preliminary analysis. The 61st Annual Scientific Meeting of the College on Problems of Drug Dependence 1999.
5. Bodenmann S., Xu S., Luhmann U.F.O., Arand M., Berger W., Jung H.H., Landolt H.P. Pharmacogenetics of modafinil after sleep loss: catechol-O-methyltransferase genotype modulates waking functions but not recovery sleep. Clin. Pharmacol. Ther. 2009, 85:296-304.
6. Braine N., Des Jarlais D.C., Goldblatt C., Zadoretzky C., Turner C. HIV risk behavior among amphetamine injectors at U.S. syringe exchange programs. AIDS Educ. Prev. 2005, 17:515-524.
7. Carroll, K.M., 1998. A cognitive-behavioral approach: treating cocaine addiction. NIDA Therapy Manuals for Drug Addiction, Bethesda, MD.
8. Cephalon Inc. Provigil (modafinil) Tablets [C-IV], FDA Approved Package Insert 2008, Cephalon, Inc., Frazier, PA.
9. Colfax G., Coates T.J., Husnik M.J., Huang Y., Buchbinder S., Koblin B., Chesney M., Vittinghoff E. Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men. J. Urban Health 2005, 82:i62-70.
10. Cruickshank C.C., Dyer K.R. A review of the clinical pharmacology of methamphetamine. Addiction (Abingdon, England) 2009, 104:1085-1099.
11. Cruickshank C.C., Montebello M.E., Dyer K.R., Quigley A., Blaszczyk J., Tomkins S., Shand D. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal. Drug Alcohol Rev. 2008, 27:326-333.
12. Dackis C.A., Kampman K.M., Lynch K.G., Pettinati H.M., O'Brien C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005, 30:205-211.
13. De La Garza, R., 2nd, Zorick, T., London, E.D., Newton, T.F., 2009. Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers. Drug Alcohol Depend., electronic publication, Sept 23, 2009.
14. Elkashef A.M., Rawson R.A., Anderson A.L., Li S.H., Holmes T., Smith E.V., Chiang N., Kahn R., Vocci F., Ling W., Pearce V.J., McCann M., Campbell J., Gorodetzky C., Haning W., Carlton B., Mawhinney J., Weis D. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 2008, 33:1162-1170.
15. Galloway G.P., Newmeyer J., Knapp T., Stalcup S.A., Smith D. A controlled trial of imipramine for the treatment of methamphetamine dependence. J. Subst. Abuse Treat. 1996, 13:493-497.
16. Hart C.L., Haney M., Vosburg S.K., Rubin E., Foltin R.W. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008, 33:761-768.
17. Heinzerling K.G., Shoptaw S., Peck J.A., Yang X., Liu J., Roll J., Ling W. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006, 85:177-184.
18. Hunter M.D., Ganesan V., Wilkinson I.D., Spence S.A. Impact of modafinil on prefrontal executive function in schizophrenia. Am. J. Psychiatry 2006, 163:2184-2186.
19. Jayaram-Lindstrom N., Hammarberg A., Beck O., Franck J. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am. J. Psychiatry 2008, 165:1442-1448.
20. Johnson B.A., Ait-Daoud N., Elkashef A.M., Smith E.V., Kahn R., Vocci F., Li S.H., Bloch D.A. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. Int. J. Neuropsychopharmacol. 2008, 11:1-14.
21. Lee N.K., Rawson R.A. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev. 2008, 27:309-317.
22. Ling W., Shoptaw S., Wesson D., Rawson R.A., Compton M., Klett C.J. Treatment effectiveness score as an outcome measure in clinical trials. NIDA Res. Monogr. 1997, 175:208-220.
23. Longo M., Wickes W., Smout M., Harrison S., Cahill S., White J.M. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction (Abingdon, England) 2009, 21. (electronic publication October).
24. Madras B.K., Xie Z.H., Lin Z.C., Jassen A., Panas H., Lynch L., Johnson R., Livni E., Spencer T.J., Bonab A.A., Miller G.M., Fischman A.J. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J. Pharmacol. Exp. Ther. 2006, 319:561-569.
25. McElhiney M.C., Rabkin J.G., Rabkin R., Nunes E.V. Provigil (modafinil) plus cognitive behavioral therapy for methamphetamine use in HIV+ gay men: a pilot study. Am. J. Drug Alcohol Abuse 2009, 35:34-37.
26. McGaugh J., Mancino M.J., Feldman Z., Chopra M.P., Gentry W.B., Cargile C., Oliveto A. Open-label pilot study of modafinil for methamphetamine dependence. J. Clin. Psychopharmacol. 2009, 29:488-491.
27. McGregor C., Srisurapanont M., Mitchell A., Wickes W., White J.M. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. J. Subst. Abuse Treat. 2008, 35:334-342.
28. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., Pettinati H., Argeriou M. The fifth edition of the addiction severity index. J. Subst. Abuse Treat. 1992, 9:199-213.
29. Minzenberg M.J., Carter C.S. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008, 33:1477-1502.
30. Minzenberg M.J., Watrous A.J., Yoon J.H., Ursu S., Carter C.S. Modanfinil shifts human locus coeruleus to low-tonic. High-phasic activity during functional MRI. Science 2008, 322:1700-1702.
31. Monterosso J.R., Aron A.R., Cordova X., Xu J.S., London E.D. Deficits in response inhibition associated with chronic methamphetamine abuse. Drug Alcohol Depend. 2005, 79:273-277.
32. National Association of Counties, 2007. The Meth Epidemic: The changing demographics of methamphetamine. (accessed on September 7, 2008). http://www.naco.org/Template.cfm?Section=Meth_Action_Clearinghouse.
33. O'Brien C.P., Dackis C.A., Kampman K. Does modafinil produce euphoria?. Am. J. Psychiatry 2006, 163:1109.
34. Powell D., Kaplan E., Whitla D., Weintraub S., Catlin R., Funkenstein H. MicroCog™: Assessment of Cognitive Functioning 2004, Windows® Edition Pearson Education, Inc., San Antonio, TX.
35. Qu W.M., Huang Z.L., Xu X.H., Matsumoto N., Urade Y. Dopaminergic D-1 and D-2 receptors are essential for the arousal effect of modafinil. J. Neurosci. 2008, 28:8462-8469.
36. Randall D.C., Fleck N.L., Shneerson J.M., File S.E. The cognitive-enhancing properties of modafinil are limited in non-sleep-deprived middle-aged volunteers. Pharmacol. Biochem. Behav. 2004, 77:547-555.
37. Randall D.C., Shneerson J.M., File S.E. Cognitive effects of modafinil in student volunteers may depend on IQ. Pharmacol. Biochem. Behav. 2005, 82:133-139.
38. SAMHSA Office of Applied Statistics, 2005. NSDUH Report. Methamphetamine Use, Abuse, and Dependence: 2002, 2003, and 2004. (accessed on September 7, 2008). http://www.drugabusestatistics.samhsa.gov/2k5/meth/meth.htm.
39. SAMHSA Office of Applied Statistics, 2007. National Survey on Drug use and Health. (accessed on September 7, 2008). http://www.oas.samhsa.gov/nsduhLatest.htm.
40. Schnoll R.A., Wileyto E.P., Pinto A., Leone F., Gariti P., Siegel S., Perkins K.A., Dackis C., Heitjan D.F., Berrettini W., Lerman C. A placebo-controlled trial of modafinil for nicotine dependence. Drug Alcohol Depend. 2008, 98:86-93.
41. Shearer J., Darke S., Rodgers C., Slade T., van Beek I., Lewis J., Brady D., McKetin R., Mattick R.P., Wodak A. A double-blind, placebo-controlled trial of modafinil (200mg/day) for methamphetamine dependence. Addiction (Abingdon, England) 2009, 104:224-233.
42. Shoptaw S., Heinzerling K.G., Rotheram-Fuller E., Steward T., Wang J., Swanson A.N., De La Garza R., Newton T., Ling W. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2008, 96:222-232.
43. Shoptaw S., Huber A., Peck J., Yang X., Liu J., Jeff D., Roll J., Shapiro B., Rotheram-Fuller E., Ling W. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006, 85:12-18.
44. Simon S.L., Domier C., Carnell J., Brethen P., Rawson R., Ling W. Cognitive impairment in individuals currently using methamphetamine. Am. J. Addict. 2000, 9:222-231.
45. Spitzer R., Williams J., Gibbbon M., First M. The Structured Clinical Interview for DSM-IV 1995, American Psychiatric Press, Washington, D.C.
46. Steer R.A., Clark D.A., Beck A.T., Ranieri W.F. Common and specific dimensions of self-reported anxiety and depression: the BDI-II versus the BDI-IA. Behav. Res. Ther. 1999, 37:183-190.
47. Stout R.L., Wirtz P.W., Carbonari J.P., Del Boca F.K. Ensuring balanced distribution of prognostic factors in treatment outcome research. J. Stud. Alcohol Suppl. 1994, 12:70-75.
48. Substance Abuse Mental Health Services Administration.Office of Applied Studies Treatment Episode Data Set (TEDS). Highlights-2007 2009, National Admissions to Substance Abuse Treatment Services, Rockville, MD.
49. Terplan M., Smith E.J., Kozloski M.J., Pollack H.A. Methamphetamine use among pregnant women. Obstet. Gynecol. 2009, 113:1285-1291.
50. Tiihonen J., Kuoppasalmi K., Fohr J., Tuomola P., Kuikanmaki O., Vorma H., Sokero P., Haukka J., Meririnne E. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am. J. Psychiatry 2007, 164:160-162.
51. United Nations Office on Drugs and Crime, 2008. World Drug Report, 2008. Vienna, Austria.
52. Volkow N.D., Fowler J.S., Logan J., Alexoff D., Zhu W., Telang F., Wang G.J., Jayne M., Hooker J.M., Wong C., Hubbard B., Carter P., Warner D., King P., Shea C., Xu Y.W., Muench L., Apelskog-Torres K. Effects of modafinil on dopamine and dopamine transporters in the male human brain clinical implications. JAMA 2009, 301:1148-1154.
53. Vosburg S.K., Hart C.L., Haney M., Rubin E., Foltin R.W. Modafinil does not serve as a reinforcer in cocaine abusers. Drug Alcohol Depend. 2009, 22. (electronic publication September).
54. Weinberger A.H., Sofuoglu M. The impact of cigarette smoking on stimulant addiction. Am. J. Drug Alcohol Abuse 2009, 35:12-17.
55. Winder-Rhodes S., Chamberlain S., Idris M., Robbins T., Sahakian B., Muller U. Effects of modafinil and prazosin on cognitive and physiological functions in healthy volunteers. J. Psychopharmacol. 2009, 3. (electronic publication June).
56. Wisor J.P., Nishino S., Sora I., Uhl G.H., Mignot E., Edgar D.M. Dopaminergic role in stimulant-induced wakefulness. J. Neurosci. 2001, 21:1787-1794.